Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system

Neuroscience Letters
Zhirui GuoMei Han

Abstract

Parkinson's disease is a neurodegenerative disorder characterized by a loss of nigrostriata dopaminergic neurons, which has been thought, at least in part, to result from oxidative stress. The present study aims to investigate the neuroprotective effects of stemazole (ST) on the dopamine (DA) system and its possible mechanisms of action in a mouse model of PD. Mice were injected intraperitoneally with MPTP (20mg/kg) four times at 2-h intervals for one day to induce Parkinsonism, and then treated with ST (10, 30 and 50mg/kg) or Madopar (120mg/kg) for 7days. Behavioral analyses were performed with locomotor activity measures and rotarod test. Tyrosine hydroxylase (TH) and dopamine transporter (DAT) levels were detected by immunohistochemistry method. DA and its metabolites were determined by high-performance liquid chromatography with an electrochemical detector. Oxidative stress levels were assessed by measuring the activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-PX). Our results demonstrated that ST treatment improved locomotor activity and motor coordination in MPTP mice. There was also a significant increase in TH-positive cells (∼24%, P<0.01) and DAT levels (∼26%, P<0.01) in MPTP mice treated with ST...Continue Reading

References

Jul 1, 1990·Journal of the Neurological Sciences·B R BloemJ W Langston
Sep 1, 1995·Neurodegeneration : a Journal for Neurodegenerative Disorders, Neuroprotection, and Neuroregeneration·V Jackson-LewisS Przedborski
Dec 1, 1996·Neurology·P Jenner, C W Olanow
Feb 18, 2003·Journal of Neurology, Neurosurgery, and Psychiatry·A WinogrodzkaE C Wolters
Mar 16, 2007·European Journal of Pharmacology·Xingchao GengXiaoping Pu
Apr 3, 2007·Nature Protocols·Vernice Jackson-Lewis, Serge Przedborski
Oct 24, 2007·Neurology·J Eric Ahlskog
Apr 10, 2008·British Medical Bulletin·C A Davie
Aug 16, 2008·Ageing Research Reviews·Renã A SowellD Allan Butterfield
Jun 24, 2009·European Journal of Pharmacology·Dingzhen LuoXiaomin Wang
Jul 17, 2009·Molecular Genetics and Metabolism·Peter J Mc GuireGeorge A Diaz
Mar 10, 2010·Behavioural Brain Research·Tonya N TaylorGary W Miller
Mar 17, 2010·Neuroscience Letters·Hong-Ning ZhangXiao-Ping Pu
Oct 13, 2010·The Journal of Biological Chemistry·Shizuma IshikawaSanae M M Iguchi-Ariga
Feb 15, 2011·European Journal of Pharmacology·Mei HanJin-Ming Zhang
Feb 18, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Jonas A HospAndreas R Luft
Oct 7, 2011·Journal of Signal Transduction·Hang CuiHong Zhang
Sep 15, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·Bernard RavinaIra Shoulson

❮ Previous
Next ❯

Citations

Apr 26, 2016·Oxidative Medicine and Cellular Longevity·Dolores Limongi, Sara Baldelli
Jun 27, 2017·Acta Pharmacologica Sinica·Qiu-Shuang ZhangNai-Hong Chen
Oct 12, 2017·Molecular Neurobiology·Cornelius J H M KlemannJasper E Visser
Sep 6, 2018·Current Neuropharmacology·Yulia A SidorovaNariman F Salakhutdinov
Nov 17, 2019·Journal of Molecular Neuroscience : MN·Manish Kumar TripathiMahendra Pratap Singh
Oct 22, 2020·Antioxidants·E Maruthi Prasad, Shih-Ya Hung
Feb 18, 2020·Current Pharmaceutical Design·Mohan K GhantaBhaskar L V K S

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Atypical Parkinsonism (MDS)

Atypical Parkinsonism presents with the same signs and symptoms of Parkinson's disease, but do not respond to typical Parkionson's disease treatment with levodopa. Atypical Parkinsonism is thought to be associated with abnormal protein buildup within brain cells. Here is the latest on Atypical Parkinsonism.